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Histone deacetylases (HDACs) play important roles in inflammatory diseases like asthma and chronic
obstructive pulmonary disease (COPD). Unravelling of and interfering with the functions of specific
isoenzymes contributing to inflammation provides opportunities for drug development. Here we syn-
thesize proteolysis targeting chimeras (PROTACs) for degradation of class I HDACs in which o-amino-
anilide-based class I HDAC inhibitors are tethered to the cereblon ligand pomalidomide. One of these
PROTACs, denoted HD-TAC7, showed promising degradation effects for HDAC3 with a DC50 value of
0.32 mM. In contrast to biochemical evidence using siRNA, HD-TAC7 showed a minimal effect on gene
expression in LPS/IFNg-stimulated RAW 264.7 macrophages. The lack of effect can be attributed to
downregulation of the NF-kB subunit p65, which is a known side effect of pomalidomide treatment.
Altogether, we describe a novel PROTAC that enables selective downregulation of HDAC3 levels, however
we note that concomitant downregulation of the NF-kB subunit p65 can confound the biological
outcome.
© 2020 Elsevier Masson SAS. All rights reserved.1. Introduction
Acetylation of lysine residues of cellular proteins plays a key role
in the regulation of cellular signal transduction pathways. The
turnover of lysine acetylation of histone proteins as well as non-
histone proteins is regulated by lysine deacetylases such as the
histone deacetylases (HDACs) and lysine acetyl transferases such as
histone acetyl transferases (HATs). Currently, eighteen HDAC iso-
enzymes, which can be divided into four classes, have been
discovered. The classes I, II, and IV contain the zinc-dependent
HDACs 1e11, while class III consists of the NAD þ -dependent sir-
tuins (SIRT1-7) [1,2]. Among them, class I HDACs, containing
HDAC1, 2, 3 and 8, are well-known for their importance in cell
motility, immunoregulation, and proliferation [3]. In order to
exploit these enzymes in drug discovery it is important to identify
the roles of these enzymes in pathology.
Several reports have shown that the class I HDACs 1, 2 and 3 are
involved in immune responses [4e6]. HDACs can affect the acety-
lation status of transcription factors involved in inflammation, suchserved.as NF-kB. Stability and DNA binding capability of NF-kB are influ-
enced by its acetylation status (as reviewed [7e9]). Consequently,
HDAC inhibition could affect NF-kB acetylation, which in turn in-
fluences expression of inflammatory genes. Previously, we reported
anti-inflammatory activity for the HDAC1,2, and 3 selective inhib-
itor Entinostat both in vitro and in vivo, which is connected to
upregulation of the anti-inflammatory cytokine Interleukin-10 (IL-
10) [10]. Mechanistically this could be linked to increased acetyla-
tion, nuclear localization and IL-10 promotor binding by the p65
subunit of the NF-kB transcription factor. Interestingly, siRNA
mediated knockdown of HDAC3 upregulated expression of IL-10 in
lipopolysaccharides (LPS)/interferong (IFNg) treated RAW 264.7
macrophages [11]. In contrast, the HDAC3 selective inhibitor,
RGFP966, did not show significant effects on gene expression in
RAW 264.7 macrophages [12]. This discrepancy between siRNA
mediated knockdown and HDAC3 selective inhibition of deacety-
lase activity suggests that this proteins functions as a scaffold rather
than as a catalyst in inflammatory signaling.
These results indicate that HDAC isoenzymes have potential in
drug discovery but that inhibition of the HDAC3 isoenzyme using
an HDAC3 selective inhibitor is not sufficient to induce an anti-
inflammatory effect. This problem might be resolved by a novel
strategy that utilizes “Proteolysis targeting chimera (PROTAC)” to
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dation of HDAC3 [13,14]. Towards this aim, PROTACs were designed
by covalent linkage of a selective HDAC inhibitor to a ligand for E3
ubiquitin ligase that are connected via a linker of variable length.
Binding of the PROTACs to both the HDAC and the E3 ligase induces
the formation of a ternary complex. Formation of this complex
triggers subsequent ubiquitination of the target protein and
degradation through the UPS [13,15,16]. To date, the reported
PROTACs mainly contain ligands for E3 ligases such as Cereblon
(CRBN) and Von Hippel-Lindau (VHL) that enable recruitment of E3
ligase activity to the target protein [16,17]. Considering this, PRO-
TACs can provide interesting novel tools to study the functional
behavior of HDACs [18], which could ultimately provide conceptual
novel opportunities for drug discovery [13,19].
Prior studies report that PROTAC mediated degradation of
HDACs is feasible for class II HDAC6 [20e22] and class III HDAC
sirtuin 2 [23]. All the reported HDAC targeting PROTACs contain
pomalidomide derivatives as E3 ligase to recruit Cereblon for tar-
geted protein degradation. This indicates that Cereblon can be used
as E3 ligase to design PROTACs for HDAC family enzymes.
Substituted o-aminoanilide derivatives bind specifically to the
active site of class I HDACs 1, 2 and 3 [24,25]. Two of these in-
hibitors, Entinostat and CI994, are currently in clinical trials. Enti-
nostat is in phase II clinical trials, while CI994 is in phase III clinical
trials [26] (Fig. 1A). In addition, the o-aminoanilide core provides
slow-tight binding [27,28], which might be beneficial for the
development of PROTACs. Therefore, we applied o-aminoanilide as
a class I HDAC binding motif to obtain ligands targeting the active
site of HDAC1, 2 and 3. By including pomalidomide as Cereblon E3
ligase ligand, a series of HDAC-PROTACs (HD-TACs) were synthe-
sized in which the length of the linker between the HDAC inhibitor
and the Cereblon ligand were varied (Fig. 1B). Here, we report a
novel class of class I HDAC directed PROTACs that include o-ami-
noanilide-based class I HDAC ligands and pomalidomide as ligand
for CRBN E3 ligase.
2. Results and discussion
2.1. Chemistry
The synthetic routes towards the HD-TACs are outlined in
Scheme 1. The ligands for HDAC 2a and 2b were synthesized
starting from Boc-protected ortho-amino aniline or Boc-protected
para-fluoro ortho-amino aniline. These building blocks were
linked to 4-nitrobenzoyl chloride following reported procedures
[29,30]. Subsequently, the nitro-group was reduced to an amine
using palladium on carbon (Pd/C) under hydrogen atmosphere to
afford 3a and 3b with yields of 42% and 53%, respectively. A
condensation reaction was applied to couple intermediate 3a with
benzyloxycarbonyl (Cbz) protected amino acid linkers using EDCI
and HOBt as reagents to obtain intermediates 4a-4c in yields be-
tween 40 and 60%, while intermediate 3b was used to obtain in-
termediate 4d using the same method with a yield of 56%. The Cbz
protective group was removed by hydrogenolysis using Pd/C as a
catalyst to afford compounds 5a-5dwith yield between 95 and 99%.
Subsequently, 5a-5d were linked to the CRBN E3 ligase ligands
using either 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-
dione or (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)
glycine using previously described procedures [31,32]. The com-
pounds 6a-6d were achieved by coupling compounds 5a-5d with
(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine
employing an amidation reaction. The following Boc-deprotection
of compounds 6a-6d provided compounds 7a-7d (code with HD-
TAC6, HD-TAC1, HD-TAC5 and HD-TAC7, Scheme 1). Compounds
8a-8c were formed by substitution reaction of 2-(2,6-2
dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione with com-
pounds 5a-5c. The subsequent Boc-deprotection of compounds 8a-
8c afforded the compounds 9a¡9c (code with HD-TAC4, HD-TAC2
and HD-TAC3).
2.2. Biological evaluation
The compounds synthesized above were subjected to HDAC
inhibition studies using HDAC1, 2 and 3, which provided IC50 values
that are similar to the IC50 values of CI994 (Table 1). These result
indicate that class I HDAC binding is retained for these HD-TACs.
The effects on cell viability were investigated and showed that
more than 80% of RAW264.7 macrophages survived treatment with
HD-TAC1-6 at concentrations up to 10 mM for 24h. Furthermore,
HD-TAC1-6 proved to be less toxic than CI994, which inhibited cell
proliferation by 30% upon treatment with 3 mM for 24h (Figure S2).
PROTACs can have highly specific effects on degradation of their
targets, because they need to form stable protein ternary com-
plexes to provide the proper protein-protein interactions between
the E3 ubiquitin ligase and the target protein for ubiquitination and
subsequent degradation [12,26e28]. Therefore, the linker length
between the E3 ligase ligand and the target protein ligands needs to
be optimized to improve the potency and selectivity of HDAC
degradation [32,33,34]. Towards this aim, a series of HD-TACs with
a variable linker length was synthesized and their potency to
degrade HDACs in macrophages was investigated. We performed a
screening of HD-TACs with different linker lengths at 10 mM for 24h
in RAW264.7 macrophages. Using western blot the protein levels
were analyzed (Fig. 2), which demonstrated an interesting pattern
of selectivity and potency with respect to HDAC degradation.
Although all the HD-TACs bind to HDAC1, none of these HD-TACs
obviously triggered HDAC1 degradation. HD-TAC3 and HD-TAC5
triggered the most obvious degradation of HDAC2, whereas HD-
TAC1 and 4 only triggered degradation of HDAC3. Among the
amide-containing HD-TACs, HD-TAC1 and 5 provided HDAC3
degradation, while HD-TAC6 did not. This difference can be
attributed to the shorter linker in HD-TAC6 compared to HD-TAC1
and 5. Although HD-TAC3, 4 and 5 triggered degradation of
HDAC3, both the potency and selectivity of HD-TAC1 appeared to be
the best. Therefore, HD-TAC1 was chosen as a starting point to
develop a selective HDAC3 degrading PROTAC. Subsequently, we
tested the degradation potency and selectivity of HD-TAC1 among
HDACs 1, 2 and 3 using concentrations ranging from 1 mM to
100 mM (data on cell viability are shown in the supporting infor-
mation). The concentration dependence shows HDAC3 degradation
by HD-TAC1 at concentrations of 10 mM and higher. This might be
due to differences in sub-cellular localization among HDAC1, 2 and
3. HDAC1 and 2 are mainly located in the nucleus, while HDAC3 is
located both in the nucleus and cytoplasm [35]. However, at con-
centrations of 30 mM and higher degradation of HDAC1 was
observed, whereas HDAC2 degradation was only observed at
100 mM. We also tested the HDAC3 degradation effect with HD-
TAC1 in A549 cells, however, in these cells HDAC3 degradation
was not observed in concentrations up to 50 mM (Figure S5). This
indicates that PROTAC mediated degradation also depends on the
cell type under investigation [20,31]. Taken together, we demon-
strated that the linker length drives the selectivity among these
HD-TACs, and HD-TAC1 showed selective HDAC3 degradation at a
lower concentration, whereas this selectivity was not observed at
higher concentrations.
HD-TAC1 was used as a starting point to gain selectivity among
HDAC1, 2 and 3. Towards this aim, we modified the o-aminoanilide
with a fluorine atom (HD-TAC7), which is known to increase HDAC3
inhibitory selectivity [24]. The inhibitory potency among HDACs 1,
2 and 3 was investigated and showed that HD-TAC7 gained
Fig. 1. (A) Chemical structures of representative o-aminoanilide derivatives as class I HDAC inhibitors (o-aminoanilide scaffold is marked in orange). (B) Conceptual PROTAC design
for targeting HDACs and design of the class I HDAC PROTACs. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this
article.)
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The concentration dependence of HD-TAC7 towards HDAC1, 2
and 3 degradation in RAW 264.7 cells was investigated (Fig. 3A).
HD-TAC7 mediated degradation of HDAC3 with a DC50 (50%
degradation concentration) value of 0.32 mM as identified by pro-
tein quantification upon western blot analysis (Fig. 3B). For HDAC1
and 2 no significant degradation was observed. A time-dependent
analysis of HD-TAC7 treatment of RAW 264.7 cells displayed fast
response in cells, and HD-TAC7-induced HDAC3 degradation
reached themaximal effect at 6h and lasted at least 48h (Fig. 3C and
D). To explore whether HD-TAC7 affected histone acetylation level
in macrophages, we tested HDAC3-mediated histone3 lysi-
ne27(H3K27) acetylation level using western blot [36]. As shown in
Fig. 3E and F, HD-TAC7 induced an increase of H3K27 acetylation in
RAW 264.7 macrophages.
Further experiments were done to confirm the importance of
both the HDAC ligand as well as the Cereblon ligand for the
observed HDAC3 degradation. Cells were treated with free poma-
lidomide or CI994 to compete with the HD-TAC for binding to CRBN3
or HDAC respectively. Cells were pre-treated with pomalidomide or
CI994 for 1h, followed by addition of HD-TAC7 for combination
treatment during 24h (Fig. 4A and B). Both combined treatment of
HD-TAC7 with pomalidomide or CI994 rescued HDAC3 degrada-
tion, indicating that degradation of HDAC3 byHD-TAC7 is Cereblon-
dependent. The proteasome inhibitor Bortezomib also completely
blocked the degradation of HDAC3 by HD-TAC7 (Fig. 4C), indicating
that HDAC3 degradation by HD-TAC7 depends on proteasome ac-
tivity. These data provide evidence that HD-TAC7 induces E3 ligase
dependent ubiquitination and subsequent proteasome mediated
HDAC3 degradation.
Subsequently, we investigated the effect of HD-TAC7 treatment
on pro- and anti-inflammatory gene transcription in RAW
264.7 cells. We employed LPS/IFNg-stimulated RAW 264.7 cells to
monitor the transcription of tumor necrosis factor a (TNFa),
interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS) as
pro-inflammatory genes and the transcription of IL-10 as anti-
inflammatory gene [10,12]. As observed previously, Entinostat
increased the expression of both pro- and anti-inflammatory genes,
Scheme 1. Reaction conditions: (a) 4-nitrobenzoyl chloride, Et3N, DCM, r.t.; (b) H2, Pd/C, methanol, r.t.; (c) Cbz-protected aliphatic carboxylic acids, EDCI, HOBt, DCM, Et3N, r.t.; (d)
(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine, EDCI, HOBt, DCM, Et3N, r.t.; (e) TFA, DCM, r.t.; (f) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, DIPEA,
DMF, 80 C.
Table 1
Binding affinities of HD-TACs.
Name Linker HDAC IC50 (mM±SD)
HDAC1 HDAC2 HDAC3
CI994 e 0.13 ± 0.01 0.83 ± 0.14 0.19 ± 0.02
HD-TAC1(7b) 0.29 ± 0.01 0.62 ± 0.04 0.52 ± 0.06
HD-TAC2(9b) 0.42 ± 0.03 1.0 ± 0.07 1.0 ± 0.09
HD-TAC3(9c) 0.22 ± 0.02 0.97 ± 0.12 0.54 ± 0.08
HD-TAC4(9a) 0.36 ± 0.03 1.2 ± 0.08 0.87 ± 0.1
HD-TAC5(7c) 0.24 ± 0.03 0.75 ± 0.05 0.33 ± 0.03
HD-TAC6(7a) 0.32 ± 0.02 1.5 ± 0.1 0.56 ± 0.07
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not show significant effects on IL-10 gene expression, which is not
in line with the biochemical evidence from previous work. In our
previous work, we found that siRNA knockdown of HDAC3
increased IL-10 gene expression [11]. In addition, treatment with
the class I selective HDAC inhibitor Entinostat upregulated IL-10
gene expression, which could be connected to increased NF-kB
p65 acetylation, increased p65 nuclear localization and increased4
binding to the IL-10 promoter [10]. HD-TAC7 showed a similar in-
fluence on all the pro- and anti-inflammatory gene transcription
levels as pomalidomide. It was reported that pomalidomide
decreased the NF-kB p65 concentration and promoted the che-
mosensitization of pancreatic cancer in human pancreatic cancer
cells [37]. We suspected that the failure to reproduce the results
from siRNA mediated knockdown of HDAC3 using a PROTAC might
be attributed to the effect of the CRBN ligand pomalidomide on the
expression levels of the NF-kB transcription factor. Therefore, we
analyzed the NF-kB p65 protein level in HD-TAC7 treated RAW
264.7 cells, together with pomalidomide and CI994 as control
(Fig. 6A). Interestingly, both treatments with HD-TAC7 and poma-
lidomide provide downregulation of NF-kB p65 in RAW 264.7
macrophages. Considering that NF-kB p65 is an active transcription
factor of IL-10 [10] the downregulation of NF-kB p65 could be the
reason that HD-TAC7 failed to increase IL-10 gene transcription.
Apparently, the use of pomalidomide as cereblon E3 ligase ligand in
PROTACs can downregulate NF-kB p65, thus interfering with NF-kB
signaling. We also tested the potency of pomalidomide analogs,
such as thalidomide and lenalidomide, in the regulation of NF-kB
p65 protein expression level. As shown in Fig. 6B, pomalidomide
analogs also downregulate the NF-kB p65 levels, which indicates
that pomalidomide analogs can not be used to alleviate the prob-
lem of NF-kB p65 downregulation. Taken together, it is important to
note that the effects of pomalidomide and its analogs on the NF-kB
p65 subunit should be taken into consideration when designing
PROTACs directed at HDAC family enzymes or other proteins.
3. Conclusion
In this study, we reported the development of a novel PROTAC
for HDAC3 degradation by tethering the CRBN ligand pomalido-
mide and o-aminoanilide-based class I HDAC inhibitors. By varying
the length of the linker between both ligands, we were able to
identify HD-TAC1, which degraded HDAC3 at 10 mM concentration
in RAW 264.7 macrophages, whereas HDAC1 and 2 were also
degraded at higher concentrations. Apparently, even nuclear
Fig. 2. (A) Analysis of the HDAC1, HDAC2 and HDAC3 protein levels upon treatment with HD-TAC1-6 at 10 mM in RAW 264.7 macrophages. (B) The bands of Fig. 2A were quantified
using Image J and plotted. Average and standard deviations of 2 independent experiments are plotted as fold of the untreated control. (C) Western blot analysis of the HDAC1,
HDAC2 and HDAC3 protein levels upon treatment of RAW 264.7 macrophages with HD-TAC1 using a range of HD-TAC1 concentrations for 24h.
Table 2
Binding affinities of HD-TAC1 and HD-TAC7.
Name R HDAC IC50 (mM±SD)
HDAC1 HDAC2 HDAC3
HD-TAC1(7b) H 0.29 ± 0.01 0.62 ± 0.04 0.52 ± 0.06
HD-TAC7(7d) F 3.6 ± 0.5 4.2 ± 0.9 1.1 ± 0.1
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ment. We note that the effectiveness of the PROTAC mediated
degradation depends on the type of cell line used, since we did not
observe HDAC3 degradation in A549 cells. HDAC3 selectivity was
improved by using a para-fluoro ortho-amino anilide core to pro-
vide HD-TAC7. HD-TAC7 showed improved potency and selectivity
for HDAC3 degradation compared to HD-TAC1 and reached a DC50
value of 0.32 mM in RAW 264.7 macrophages. Controls confirmed
that degradation disappears upon competition with the HDAC
ligand as well as the CRBN E3 ligase ligand. Application of HD-TAC7
in LPS/IFNg stimulated RAW 264.7 macrophages showed that HD-
TAC7 did not significantly affect gene transcription of IL-10, iNOS,
IL-6 and TNFa in contrast to the HDAC inhibitors Entinostat and
CI994. The lack of effect might be caused by a side effect of treat-
ment with the pomalidomide CRBN E3 ligase ligand since it
downregulates the levels of the NF-kB p65 subunit. Thus, PROTACs
using this ligand will unintendedly interfere with signaling via this
pathway, which plays crucial roles in many processes. Taken
together, our results contribute to understanding the parameters
important for PROTAC design, which provides a basis for further5
development this novel type of molecular tools for applications in
cell-based studies and ultimately drug discovery.
4. Experimental section
4.1. Chemistry
General. The solvents and reagents were purchased from
Sigma-Aldrich, Acros chemicals or abcr GmbH without further
purification. Reactions were monitored by thin layer chromatog-
raphy (TLC). Merck silica gel 60 F254 plates were used and spots
were detected under UV light or after staining with potassium
permanganate for the non UV-active compounds. MP Ecochrom
silica 32e63, 60 Å was used for flash column chromatography. 1H
NMR (500 MHz) and 13C NMR (126 MHz) spectra were recorded
with a Bruker Avance 4-channel NMR Spectrometer with TXI probe.
Chemical shifts were referenced to the residual proton and carbon
signal of the deuterated solvent CDCl3: d ¼ 7.26 ppm (1H) and
77.05 ppm (13C), (CD3)2SO: d ¼ 2.50 ppm (1H) and 39.52 ppm (13C)
CD3OD: d ¼ 3.31 ppm (1H) and 49.00 ppm (13C). The following
abbreviations were used for spin multiplicity: s ¼ singlet, br.
s ¼ broad singlet, d ¼ doublet, t ¼ triplet, q ¼ quartet, p ¼ quintet,
dd ¼ double of doublets, ddd ¼ double of doublet of doublets,
m ¼ multiplet. Fourier Transform Mass Spectrometry (FTMS) was
recorded on an Orbitrap XL Hybrid Ion Trap-Orbitrap Mass Spec-
trometer to give high-resolution mass spectra (HRMS). High-
performance liquid chromatography (HPLC) analysis was per-
formed for confirming purity with a Shimadzu LC-20AD HPLC, with
a Shimadzu SP-M20A ELSD detector, and with a Shimadzu SPD-
M20A photodiode array detector. Analytical HPLC was performed
using a Kinetex C18 column (150 mm  4.6 mm, 5 mm) with
15e100% MeCN gradient in H2O as a mobile phase. Retention time
(RT) of HPLC was also reported.
4.1.1. Synthetic procedure 1: amide bond formation
A carboxylic acid derivative (1.0 equiv) was dissolved in dry
CH2Cl2 (5.0 mL) and cooled on an ice bath. The coupling reagents
EDCI (1.2 equiv) and HOBt (0.4 equiv) were added to the solution
and the reactionwas stirred on ice for 15min. Then Et3N (2.0 equiv)
Fig. 3. (A) Analysis of HDAC1, HDAC2 and HDAC3 degradation upon HD-TAC7 treatment of RAW 264.7 macrophages for 24 h using Western blot. (B) The bands of Fig. 3A were
quantified using Image J and plotted in a graph, which was used for determination of the 50% degradation concentration by non-linear curve fitting with GraphPad Prism. Average
and standard deviations of 2e3 independent experiments are plotted as percentage of the untreated control. (C) Analysis of HDAC3 degradation upon HD-TAC7 treatment of RAW
264.7 macrophages for indicated time point using Western blot. (D) The bands of Fig. 3C were quantified using Image J and plotted. Average and standard deviations of 2 inde-
pendent experiments are plotted as fold of the untreated control. (E) Analysis of acetylation level of lysine 27 on histone 3 upon CI994, Pomalidomide and HD-TAC7 treatment of
RAW 264.7 macrophages for 24h using Western blot. (F) The bands of Fig. 3E were quantified using Image J and plotted. Average and standard deviations of 2 independent ex-
periments are plotted as fold of the untreated control.
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and it was stirred at room temperature overnight. The reaction
mixture was washed with 1.0 M aqueous HCl (10 mL), saturated
aqueous NaHCO3 (10 mL), and brine (10 mL); dried over MgSO4;
filtered; and concentrated under reduced pressure. The crude
product was purified by flash column chromatography and eluted
with 20% ethyl acetate in petroleum ether as a solvent to obtain a
white solid product in yields between 40 and 65%.
4.1.2. Synthetic procedure 2: reduction reaction
Compounds containing a nitro or Cbz-protective group (1.0
equiv) were dissolved in methanol (3 mL). The solution was added
to Pd/C (0.1 equiv) and the flask was charged with hydrogen (H2)
gas. The reaction mixture was stirred at r.t. and detected with TLC
for a period from 2 h to 18 h until the solution became homoge-
neous. Finally, the reaction mixture was filtered through Celite and
evaporated under reduced pressure to obtain the final product
without further purification.
4.1.3. Synthetic procedure 3: nucleophilic substitution reaction
Boc protected alkyl amines (5a-5c) (1.1 equiv) were added to a
stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-
1,3-dione (1.0 equiv) in DMF (3.0 mL) and DIPEA (2.0 equiv). The6
reaction mixture was stirred at 80 C for 12h. Then the mixture was
cooled to room temperature, poured into cold brine and extracted
with EtOAc (3 times, 10 mL). The organic layers were combined,
washed with cold brine and dried over MgSO4. After filtration and
evaporation, the crude residue was purified by flash column chro-
matography and eluted with 5% methanol in CH2Cl2 to obtain the
product with yields ranging from 30 to 60%.
4.1.4. Synthetic procedure 4: boc deprotection
A Boc-protected compound (1.0 equiv.) was dissolved in CH2Cl2
(chemical pure, 1.5 mL). Subsequently, Trifluoroacetic acid (TFA,
1.5 mL) was added. The mixture was stirred at r.t. until the solution
became homogeneous. Themixturewas extractedwith 1.0MNaOH
(20 mL). The organic layer was collected and dried over MgSO4,
removal of the solvent under reduced pressure afforded the final
product.
4.1.5. tert-Butyl (2-(4-nitrobenzamido)phenyl)carbamate (2a)
tert-Butyl(2-aminophenyl)carbamate (2.08 g, 10 mmol) and
Et3N (2.8 mL, 20 mmol) were added in CH2Cl2 (10 mL), which was
cooled to 0 C. Then, 4-nitrobenzoyl chloride (1.9 g, 10 mmol) was
dissolved in CH2Cl2 (3 mL) and added dropwise to the mixture.
Subsequently, the reaction was stirred at room temperature
Fig. 4. (A) Analysis of the HDAC3 protein levels in RAW 264.7 macrophages. The cells were pre-treated with pomalidomide or CI994 for 1h followed by addition of HD-TAC7 for
combination treatment during 24h, while the control cells were treated with CI994 or pomalidomide for 25h. (B) The bands of Fig. 4A were quantified using Image J and plotted.
Average and standard deviations of 2 independent experiments are plotted as fold of the untreated control. (C) Analysis of the HDAC3 protein levels in RAW 264.7 macrophages. The
cells were treated with Bortezomib, HD-TAC7 or the combination of Bortezomib and HD-TAC7 for 24h. (D) The bands of Fig. 4C were quantified using Image J and plotted. Average
and standard deviations of 2 independent experiments are plotted as fold of the untreated control.
F. Cao, S. de Weerd and D. Chen et al. European Journal of Medicinal Chemistry 208 (2020) 112800overnight. Then, the reaction mixture was washed with a saturated
aqueous NaHCO3 solution (10 mL), a 1.0 M aqueous HCl solution
(10mL), and brine (10mL). The organic layer was dried over MgSO4,
filtered and concentrated under reduced pressure. The crude
product was obtained as yellow solid in an estimated yield of 91%
and used for the next step without further purification. 1H NMR
(500 MHz, Chloroform-d) d 9.78 (s, 1H), 8.32 (d, J ¼ 8.8 Hz, 2H), 8.15
(d, J¼ 8.7 Hz, 2H), 7.91 (d, J¼ 8.0 Hz,1H), 7.29 (t, J¼ 7.7 Hz,1H), 7.20
(d, J ¼ 7.8 Hz, 1H), 7.13 (d, J ¼ 7.3 Hz, 1H), 6.70 (s, 1H), 1.53 (s, 9H).4.1.6. tert-Butyl (2-(4-aminobenzamido)phenyl)carbamate(3a)
The product was obtained using synthetic procedure 2, starting
from compound 2a. Yellow oil, yield 99%.1H NMR (500 MHz,
Chloroform-d) d 8.76 (s, 1H), 7.79 (d, J ¼ 8.6 Hz, 2H), 7.71 (d,
J¼ 7.8 Hz,1H), 7.31 (d, J¼ 7.9 Hz,1H), 7.23e7.13 (m, 2H), 6.82 (s,1H),
6.70 (d, J ¼ 8.6 Hz, 2H), 4.02 (s, 2H), 1.51 (s, 9H).4.1.7. Benzyl (4-((4-((2-((tert-butoxycarbonyl)amino)phenyl)
carbamoyl)phenyl)amino)-4-oxobutyl)carbamate(4a)
The product was obtained using synthetic procedure 1, starting
from compound 3a. White solid, yield 42%. 1H NMR (500 MHz,
Chloroform-d) d 9.03 (s,1H), 8.76 (s,1H), 7.94 (d, J¼ 8.6 Hz, 2H), 7.81
(d, J ¼ 7.9 Hz, 1H), 7.73 (d, J ¼ 8.4 Hz, 2H), 7.37 (d, J ¼ 2.6 Hz, 4H),7
7.30e7.27 (m, 1H), 7.26e7.21 (m, 2H), 7.18 (td, J ¼ 7.6, 1.5 Hz, 1H),
6.72 (s, 1H), 5.14 (s, 2H), 4.99 (d, J¼ 13.1 Hz, 1H), 3.40e3.31 (m, 2H),
2.47e2.38 (m, 2H), 1.93 (p, J ¼ 6.3 Hz, 2H), 1.52 (s, 9H).4.1.8. tert-Butyl (2-(4-(5-(((benzyloxy)carbonyl)amino)
pentanamido)benzamido)phenyl)carbamate(4b)
The product was obtained using synthetic procedure 1, starting
from compound 3a. White solid, yield 53%.1H NMR (500 MHz,
Methanol-d4) d 7.94 (d, J ¼ 8.7 Hz, 2H), 7.74 (d, J ¼ 8.7 Hz, 2H),
7.61e7.57 (m, 1H), 7.45e7.41 (m, 1H), 7.33 (q, J ¼ 7.9, 7.3 Hz, 4H),
7.29e7.25 (m, 1H), 7.23 (ddd, J ¼ 6.9, 4.2, 2.0 Hz, 2H), 5.07 (s, 2H),
3.17 (t, J¼ 6.9 Hz, 2H), 2.43 (t, J¼ 7.4 Hz, 2H), 1.73 (p, J¼ 7.4 Hz, 2H),
1.58 (dt, J ¼ 14.0, 7.0 Hz, 2H), 1.50 (s, 9H).4.1.9. Benzyl (6-((4-((2-((tert-butoxycarbonyl)amino)phenyl)
carbamoyl)phenyl)amino)-6-oxohexyl)carbamate(4c)
The product was obtained using synthetic procedure 1, starting
from compound 3a. White solid, yield 40%.1H NMR (500 MHz,
Chloroform-d) d 9.10 (s, 1H), 7.93 (d, J ¼ 8.5 Hz, 2H), 7.80 (d,
J ¼ 7.8 Hz, 1H), 7.64 (d, J ¼ 8.2 Hz, 2H), 7.50 (s, 1H), 7.38e7.27 (m,
5H), 7.24 (d, J ¼ 7.7 Hz, 2H), 7.17 (td, J ¼ 7.6, 1.5 Hz, 1H), 6.74 (s, 1H),
5.09 (s, 2H), 4.81 (s, 1H), 3.22 (q, J ¼ 6.8 Hz, 2H), 2.37 (t, J ¼ 7.4 Hz,
2H), 1.77 (q, J ¼ 7.6 Hz, 2H), 1.57 (d, J ¼ 7.1 Hz, 2H), 1.52 (s, 9H), 1.41
Fig. 5. Effects of Entinostat, CI994, pomalidomide and HD-TAC7 on pro- and anti-inflammatory gene expression of (A) IL-10, (B) iNOS, (C) IL-6 and (D) TNFa in RAW 264.7
macrophages. Cells were treated with the respective HDAC inhibitors at the indicated concentrations for 24h and stimulated with LPS/IFNg for the last 4h of the experiments. Gene
transcription was analyzed by RT-qPCR. For vehicle treatment, cells were pre-treated with a proportional dilution of the inhibitor solvent DMSO. Data shown is represented as mean
values ± SD of 2e3 independent experiments. ****p < 0.0001 compared to vehicle treated-cells. **p < 0.01 compared to vehicle-treated cells.
Fig. 6. (A) Western blot analysis of NF-kB p65 in RAW 264.7 macrophages. RAW 264.7 cells were incubated with Entinostat, CI994, pomalidomide or HD-TAC7 for 24h and
stimulated with LPS and IFNa the last 4h of the experiment. (B) Analysis of NF-kB p65 protein level in RAW 264.7 macrophages using western blot. Cells were treated with
pomalidomide, HD-TAC7, thalidomide or lenalidomide for 24h.
F. Cao, S. de Weerd and D. Chen et al. European Journal of Medicinal Chemistry 208 (2020) 112800(q, J ¼ 8.0 Hz, 2H).4.1.10. tert-Butyl (2-(4-(5-(((benzyloxy)carbonyl)amino)
pentanamido)benzamido)-5-fluorophenyl)carbamate(4d)
The product was obtained using synthetic procedure 1, starting
from compound 3b. White solid, yield 56%.1H NMR (500 MHz,8
Chloroform-d) d 8.95 (s,1H), 8.21 (s,1H), 7.88 (d, J¼ 8.6 Hz, 2H), 7.63
(d, J ¼ 8.4 Hz, 2H), 7.48 (dd, J ¼ 8.7, 5.8 Hz, 1H), 7.36e7.29 (m, 5H),
7.26e7.19 (m, 2H), 6.83 (td, J ¼ 8.8, 2.8 Hz, 1H), 5.10 (s, 2H), 3.21 (p,
J ¼ 6.2 Hz, 2H), 2.37 (t, J ¼ 7.5 Hz, 2H), 1.70 (dq, J ¼ 18.9, 8.8, 8.0 Hz,
3H), 1.61e1.51 (m, 3H), 1.48 (s, 9H).
F. Cao, S. de Weerd and D. Chen et al. European Journal of Medicinal Chemistry 208 (2020) 1128004.1.11. tert-Butyl (2-(4-(5-aminopentanamido)benzamido)phenyl)
carbamate(5b)
The product was obtained using synthetic procedure 2, starting
from compound 4b. White oil, yield 95%.1H NMR (500 MHz,
Methanol-d4) d 7.94 (d, J ¼ 8.7 Hz, 2H), 7.74 (d, J ¼ 8.7 Hz, 2H), 7.60
(dd, J¼ 7.2, 1.8 Hz,1H), 7.46e7.39 (m,1H), 7.27e7.13 (m, 2H), 2.71 (t,
J ¼ 7.2 Hz, 2H), 2.44 (t, J ¼ 7.4 Hz, 2H), 1.75 (p, J ¼ 7.4 Hz, 2H),
1.62e1.55 (m, 2H), 1.50 (s, 9H).
4.1.12. tert-Butyl (2-(4-(6-aminohexanamido)benzamido)phenyl)
carbamate(5c)
The product was obtained using synthetic procedure 2, starting
from compound 4c. White oil, yield 99%. 1H NMR (500 MHz,
Chloroform-d) d 9.23 (s, 1H), 7.96 (s, 1H), 7.93e7.89 (m, 2H), 7.76
(dd, J ¼ 7.9, 1.6 Hz, 1H), 7.64 (d, J ¼ 8.4 Hz, 2H), 7.27 (d, J ¼ 1.6 Hz,
1H), 7.18 (dtd, J¼ 25.1, 7.5, 1.7 Hz, 2H), 7.12 (s, 1H), 2.71 (t, J¼ 6.8 Hz,
2H), 2.35 (t, J¼ 7.4 Hz, 2H), 1.74e1.69 (m, 2H), 1.51 (s, 9H), 1.50e1.45




The product was obtained using synthetic procedure 2 and 4,
starting from compound 5a. Yellow solid, yield 30%.1H NMR
(500MHz, DMSO‑d6) d 11.12 (s, 1H), 10.17 (s, 1H), 9.55 (s, 1H), 8.18 (t,
J ¼ 5.8 Hz, 1H), 7.94 (d, J ¼ 8.5 Hz, 2H), 7.71 (d, J ¼ 8.5 Hz, 2H),
7.64e7.56 (m, 1H), 7.16 (d, J ¼ 7.8 Hz, 1H), 7.08 (d, J ¼ 7.1 Hz, 1H),
7.00e6.94 (m, 2H), 6.88 (d, J ¼ 8.6 Hz, 1H), 6.79 (d, J ¼ 9.5 Hz, 1H),
6.60 (t, J ¼ 8.1 Hz, 1H), 5.09 (dd, J ¼ 12.8, 5.4 Hz, 1H), 4.88 (s, 2H),
3.95 (d, J ¼ 5.6 Hz, 2H), 3.18 (dd, J ¼ 5.9, 3.3 Hz, 3H), 2.95e2.84 (m,
1H), 2.66e2.52 (m, 2H), 2.38 (t, J ¼ 7.5 Hz, 2H), 2.09e2.01 (m, 1H),
1.76 (p, J ¼ 7.3 Hz, 2H). 13C NMR (126 MHz, DMSO‑d6) d 173.32,
171.75, 170.57, 169.18, 168.93, 167.80, 165.17, 146.28, 143.61, 142.53,
136.69, 132.52, 129.18, 129.13, 127.14, 126.84, 123.95, 118.55, 117.91,
116.74, 116.61, 111.43,110.32, 55.39, 49.02, 45.63, 38.67, 34.28, 31.45,
25.48, 22.64. HRMS: C32H31N7O7, mass expected [MþH] þ





The product was obtained using synthetic procedure 2 and 4,
starting from compound 5b. Yellow solid, yield 27%.1H NMR
(500MHz, DMSO‑d6) d 11.12 (s, 1H), 10.15 (s, 1H), 9.57 (s, 1H), 8.15 (t,
J ¼ 5.7 Hz, 1H), 7.94 (d, J ¼ 8.6 Hz, 2H), 7.71 (d, J ¼ 8.7 Hz, 2H),
7.62e7.56 (m, 1H), 7.16 (d, J ¼ 7.9 Hz, 1H), 7.07 (d, J ¼ 7.1 Hz, 1H),
7.00e6.93 (m, 2H), 6.87 (d, J ¼ 8.6 Hz, 1H), 6.79 (dd, J ¼ 7.9, 1.1 Hz,
1H), 6.64e6.55 (m, 1H), 5.08 (dd, J ¼ 12.8, 5.4 Hz, 1H), 4.89 (s, 2H),
3.94 (d, J¼ 5.6 Hz, 2H), 3.16 (dq, J¼ 12.7, 6.6, 5.9 Hz, 2H), 2.96e2.82
(m, 1H), 2.68e2.52 (m, 2H), 2.36 (t, J ¼ 7.3 Hz, 2H), 2.04 (dtd,
J ¼ 10.9, 5.9, 3.5 Hz, 1H), 1.61 (dt, J ¼ 14.7, 7.2 Hz, 2H), 1.47 (dt,
J ¼ 13.9, 6.7 Hz, 2H). 13C NMR (126 MHz, DMSO‑d6) d 173.31, 172.01,
170.56, 169.17, 168.80, 167.80, 165.18, 146.30, 143.61, 142.56, 136.67,
132.52, 129.17, 127.13, 126.84, 123.95, 118.54, 117.92, 116.74, 116.60,
111.40, 110.31, 55.39, 49.02, 45.64, 38.81, 36.51, 31.45, 29.15, 22.87,
22.63. HRMS: C33H33N7O7, mass expected [MþH] þ 640,25142,




The product was obtained using synthetic procedure 2 and 4,
starting from compound 5c. Yellow solid, yield 36%.1H NMR
(500MHz, DMSO‑d6) d 11.12 (s, 1H), 10.15 (s, 1H), 9.57 (s, 1H), 8.13 (t,9
J¼ 5.7 Hz,1H), 7.94 (d, J¼ 8.3 Hz, 2H), 7.72 (d, J¼ 8.3 Hz, 2H), 7.60 (t,
J¼ 7.8 Hz,1H), 7.16 (d, J¼ 7.8 Hz,1H), 7.07 (d, J¼ 7.0 Hz,1H), 6.97 (q,
J ¼ 6.8, 5.6 Hz, 2H), 6.86 (d, J ¼ 8.5 Hz, 1H), 6.79 (d, J ¼ 7.9 Hz, 1H),
6.61 (t, J ¼ 7.5 Hz, 1H), 5.09 (dd, J ¼ 12.8, 5.4 Hz, 1H), 4.92 (s, 2H),
3.93 (d, J¼ 5.0 Hz, 2H), 3.12 (q, J¼ 6.5 Hz, 2H), 2.90 (td, J¼ 17.1, 15.2,
4.9 Hz,1H), 2.66e2.53 (m, 2H), 2.35 (t, J¼ 7.5 Hz, 2H), 2.09e1.97 (m,
1H), 1.61 (p, J ¼ 7.8 Hz, 2H), 1.46 (p, J ¼ 7.1 Hz, 2H), 1.31 (p, J ¼ 7.5,
6.6 Hz, 2H). 13C NMR (126 MHz, DMSO‑d6) d 173.31, 172.08, 170.56,
169.17, 168.71, 167.80, 165.17, 158.29,146.29, 143.48, 142.59, 132.52,
129.14, 127.13, 126.83, 124.01, 118.53, 117.90, 116.82, 116.66, 111.41,
110.30, 55.39, 49.01, 38.97, 36.84, 31.45, 29.36, 26.53, 25.14, 22.63.
HRMS: C34H35N7O7, mass expected [MþH] þ 654,26707, found




The product was obtained using synthetic procedure 2 and 4,
starting from compound 5b. Yellow solid, yield 36%.1H NMR
(500MHz, DMSO‑d6) d 11.11 (s, 1H), 10.14 (s, 1H), 9.50 (s, 1H), 8.14 (t,
J ¼ 5.8 Hz, 1H), 7.93 (d, J ¼ 8.5 Hz, 2H), 7.70 (d, J ¼ 8.8 Hz, 2H),
7.61e7.54 (m, 1H), 7.10 (dd, J ¼ 8.7, 6.3 Hz, 1H), 7.06 (d, J ¼ 7.1 Hz,
1H), 6.95 (s, 1H), 6.86 (d, J ¼ 8.6 Hz, 1H), 6.55 (dd, J ¼ 11.2, 2.9 Hz,
1H), 6.37 (td, J ¼ 8.5, 2.9 Hz, 1H), 5.07 (dd, J ¼ 12.8, 5.4 Hz, 1H), 3.93
(s, 2H), 3.13 (q, J ¼ 6.6 Hz, 2H), 2.97e2.82 (m, 1H), 2.63e2.52 (m,
2H), 2.35 (t, J ¼ 7.3 Hz, 2H), 2.01 (dd, J ¼ 15.9, 8.8 Hz, 1H), 1.59 (p,
J¼ 7.4 Hz, 2H), 1.47 (q, J¼ 7.1 Hz, 2H). 13C NMR (126MHz, DMSO‑d6)
d 173.31, 172.01, 170.55, 169.16, 168.79, 167.79, 165.46, 162.35,
160.45, 155.99, 146.30,145.65, 142.58, 132.52, 129.04, 120.00, 118.43,
117.92,114.33,111.40,110.31, 49.02, 45.63, 38.80, 36.49, 31.45, 28.68,
22.57. HRMS: C33H32FN7O7, mass expected [MþH] þ 658,242, found
658,24164. HPLC: purity 98%, retention time 10.3 min.
4.1.17. N-(2-aminophenyl)-4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)butanamido)benzamide(9a)
The product was obtained using synthetic procedure 3 and 4,
starting from compound 5a. Yellow solid, yield 17%.1H NMR
(500 MHz, DMSO‑d6) d 11.09 (s, 1H), 10.29 (s, 1H), 9.60 (s, 1H), 7.93
(d, J ¼ 8.7 Hz, 2H), 7.70 (d, J ¼ 8.7 Hz, 2H), 7.59 (dd, J ¼ 8.4, 7.2 Hz,
1H), 7.18e7.13 (m, 2H), 7.03 (d, J ¼ 7.0 Hz, 1H), 6.99e6.93 (m, 1H),
6.77 (dd, J ¼ 8.0, 1.2 Hz, 1H), 6.69 (t, J ¼ 5.9 Hz, 1H), 6.63e6.56 (m,
1H), 5.04 (dd, J ¼ 12.8, 5.4 Hz, 1H), 4.88 (s, 2H), 3.45e3.39 (m, 2H),
2.88 (tdd, J ¼ 14.4, 13.9, 5.7, 4.2 Hz, 1H), 2.64e2.52 (m, 2H), 2.47 (t,
J ¼ 7.2 Hz, 2H), 2.05e1.97 (m, 1H), 1.91 (p, J ¼ 7.1 Hz, 2H). HRMS:
C30H28N6O6, mass expected [MþH] þ 569,21431, found 569,21423.
HPLC: purity 91%, retention time 10.6 min.
4.1.18. N-(2-aminophenyl)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)pentanamido)benzamide(9b)
The product was obtained using synthetic procedure 3 and 4,
starting from compound 5b. Yellow solid, yield 38%.1H NMR
(500MHz, DMSO‑d6) d 11.11 (s,1H),10.18 (s,1H), 9.56 (s,1H), 7.94 (d,
J ¼ 8.6 Hz, 2H), 7.71 (d, J ¼ 8.7 Hz, 2H), 7.60e7.55 (m, 1H), 7.14 (dd,
J ¼ 15.1, 8.0 Hz, 2H), 7.03 (d, J ¼ 7.0 Hz, 1H), 6.97 (d, J ¼ 16.7 Hz, 1H),
6.78 (d, J¼ 8.0 Hz, 1H), 6.65e6.56 (m, 2H), 5.06 (dd, J¼ 12.8, 5.5 Hz,
1H), 4.89 (s, 2H), 3.42e3.36 (m, 2H), 2.95e2.82 (m, 1H), 2.67e2.53
(m, 2H), 2.42 (t, J ¼ 7.1 Hz, 2H), 2.10e1.97 (m, 1H), 1.67 (dq, J ¼ 26.5,
8.1, 7.6 Hz, 4H). 13C NMR (126 MHz, DMSO‑d6) d 173.31, 171.98,
170.60, 169.38, 167.78, 165.87, 165.15, 156.02, 146.84, 143.60, 142.52,
136.72, 132.71, 129.21, 129.13, 127.12, 126.84, 123.95, 118.56, 117.66,
116.73, 116.58, 115.60, 114.34, 110.86, 109.52, 49.00, 42.01, 36.56,
31.44, 28.77, 22.65. HRMS: C31H30N6O6, mass expected [MþH] þ
583,22996, found 583,22986. HPLC: purity 96%, retention time
11.1 min.
F. Cao, S. de Weerd and D. Chen et al. European Journal of Medicinal Chemistry 208 (2020) 1128004.1.19. N-(2-aminophenyl)-4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)hexanamido)benzamide(9c)
The product was obtained using synthetic procedure 3 and 4,
starting from compound 5c. Yellow solid, yield 31%.1H NMR
(500 MHz, DMSO‑d6) d 11.10 (s, 1H), 10.13 (s, 1H), 9.55 (s, 1H), 7.93
(d, J ¼ 8.4 Hz, 2H), 7.70 (d, J ¼ 8.5 Hz, 2H), 7.61e7.54 (m, 1H), 7.13
(dd, J ¼ 21.9, 8.8 Hz, 2H), 7.02 (d, J ¼ 6.6 Hz, 1H), 6.96 (t, J ¼ 7.6 Hz,
1H), 6.78 (d, J ¼ 8.8 Hz, 1H), 6.65e6.51 (m, 2H), 5.05 (dd, J ¼ 12.7,
4.8 Hz, 1H), 4.87 (s, 2H), 3.21e3.11 (m, 2H), 2.94e2.82 (m, 1H), 2.58
(dd, J ¼ 17.4, 3.2 Hz, 2H), 2.36 (t, J ¼ 7.1 Hz, 2H), 2.08e1.98 (m, 1H),
1.69e1.58 (m, 4H),1.46e1.35 (m, 2H). 13C NMR (126MHz, DMSO‑d6)
d 173.32, 172.08, 170.61, 169.41,167.78, 165.17,146.88,143.61, 142.58,
136.77, 132.67, 129.15, 129.12, 127.13, 123.96, 118.54, 117.69, 116.73,
116.60, 110.86, 109.46, 48.99, 42.18, 36.87, 31.45, 29.00, 26.47, 25.23,
22.62. HRMS: C32H32N6O6, mass expected [MþH] þ 597,24561,
found 597,24564. HPLC: purity 98%, retention time 11.5 min.
4.2. HDAC inhibition study
Black 96-well flat-bottom microplates (Corning® Costar®,
Corning Incorporated, NY) were used. Human recombinant C-ter-
minal FLAG-tag, C-terminal His-tag HDAC1 (BPS Bioscience, Catalog
#: 50051), Human recombinant C-terminal FLAG-tag HDAC2 (BPS
Bioscience, Catalog #: 50052) or human recombinant C-terminal
His-tag HDAC3/NcoR2 (BPS Bioscience, Catalog #: 50003) were
diluted in incubation buffer (25 mM Tris-HCl, pH 8.0, 137 mM NaCl,
2.7 mM KCl, 1 mMMgCl, 0.01% Triton-X and 1 mg/mL BSA). 40 mL of
this dilutionwas incubatedwith 10 mL of different concentrations of
inhibitors in 10% DMSO/incubation buffer and 50 mL of the fluoro-
genic Boc-Lys(ε-Ac)-AMC (20 mM, Bachem, Germany) at 37 C.
After 90 min incubation time 50 mL of the stop solution (25 mM
Tris-HCl (pH 8), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.01%
Triton-X, 6.0 mg/mL trypsin (porcine pancreas Type IX-S, lyophi-
lized powder, 13,000e20,000 BAEE units/mg protein, Sigma
Aldrich) and 200 mM vorinostat) was added. After a following in-
cubation at 37 C for 30 min, the fluorescence was measured on a
Synergy H1 Platereader (BioTek, USA) with a gain of 70, an excita-
tion wavelength of 370 nm and an emission wavelength of 460 nm.
GraphPad Prism 5.0 (GraphPad Software, Inc.) was used for the
determination of the DC50 of each inhibitor. Nonlinear regression
was used for data fitting.
4.3. Cell viability
4.3.1. Cell culture
RAW 264.7 macrophages were obtained from the American
Type Culture Collection (ATCC; Wesel, Germany) and cultured in
96-well plate or flasks (Costar Europe, Badhoevedrop, The
Netherlands) at 37 C under 5% CO2/95% air in Dulbecco’s Modifi-
cation of Eagle’s Medium (DMEM) containing GlutaMAX™ (Gibco®
by life Technologies, Bleiswijk, The Netherlands) supplemented
with 10% (v/v) heated fetal bovine serum (FBS; Invitrogen, Breda,
The Netherlands), 2 mM additional GlutaMAX™ (Gibco® by life
Technology, Bleiswijk, The Netherlands), 100U/ml penicillin
(Gibco® by life Technologies, Bleiswijk, The Netherlands) and
100 mg/ml streptomycin (Gibco® by life Technologies, Bleiswijk, The
Netherlands). RAW 264.7 cells were used between passage 5 and
16.
4.3.2. MTS assay
RAW264.7 cells were seeded in 96-well plate at the concen-
tration of 25,000 cells/cm2. The next day, medium was replaced
with fresh medium containing HDAC inhibitors at the indicated
concentrations. After 24h incubation at 37 C, 20 ml CellTiter 96
AQueous One Solution reagent (Promega) was added to each well.10The cells were incubated at 37 C for 2h in the dark. The absorbance
at 490 nM was measured using a Synergy H1 plate reader. The
results were plotted as % of control.
4.3.3. Western blotting
RAW264.7 cells were washed twice with ice-cold DPBS and
subsequently lysed in ice-cold lysis buffer (25 mM Hepes, 5 mM
MgCl2, 5 mM EDTA, 0.5% Triton X-100 and protease inhibitors
(#88266; Thermo Scientific, Rockford, IL, USA)). Protein concen-
trations were determined by a Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific, USA) according to the manufacturer’s
protocol. Samples were separated by NuPAGE™ 4e12% Bis-Tris gel
(Invitrogen, Carlsbad, Canada), and transferred with a Trans-Blot
Electrophoretic Transfer system (Bio-Rad Laboratories) onto a
polyvinylidene difluoride membrane (PVDF; Bio-Rad Laboratories).
Themembranewas blocked at room temperature for 1h in PBS/0.1%
Tween 20 (Sigma-Aldrich; solution referred to as PBST) containing
5% skimmed milk (Campina, Friesland, The Netherlands) and sub-
sequently incubated overnight at 4 Cwith the appropriate primary
antibody in 5% BSA (Sigma-Aldrich) or 5% skimmed milk in PBST.
The following primary antibodies and dilutions were used: HDAC1
(1:2000), HDAC2 (1:2000), HDAC3 (1:2000), NF-kB p65 (1:2500),
acH3K27(1:1000) and b-actin (1:10000); all from CellSignaling,
Leiden, The Netherlands. Membranes were washed in PBST and
incubated at room temperature for 1h with peroxidase-conjugated
secondary antibodies. The following secondary antibodies were
used: goat anti-rabbit IgG/HRP, and rabbit anti-mouse IgG/HRP (all
1:2000; DakoCytomation, Glostrup, Denmark). The bands were
visualized using the VisiGlo™ Prime HRP Chemiluminescenct
Substrate Kit (AMRESCO, Solon, OH, USA). For the western blot of
0.001mMe30mMHD-TAC7-treated RAW264.7 cells were worked up
according to the protocol above until blocking the membrane. The
membrane was blocked at room temperature for 1h in Odyssey
blocking buffer. The primary antibodies and dilutions were used
above, while the fluorescent secondary antibodies were used as
following: IRDye 680RD Goat anti-Mouse IgG (H þ L) (1:10000,
Fisher Scientific) and IRDye® 800CW Goat anti-Rabbit IgG
(1:10000, LI-COR Biosciences, UK). The bands were visualized using
Odyssey® CLx Blot Scanner (LI-COR Biosciences, UK).
4.3.4. RT-qPCR
RAW264.7 cells were washed twice with Dulbecco’s Phosphate-
buffered Saline (DPBS, Gibco® by life Technologies, Bleiswijk, The
Netherlands) and total RNA was isolated by Maxwell® 16 LEV
simplyRNA Tissue Kit (Promega) according to the manufacturer’s
protocol. RNA concentration (OD260) and purity (OD260/OD280)
were measured by NanoDrop ND-1000 UVeVis spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). Then, RNA was
reverse transcribed to cDNA using the Reverse Transcription Kit
(#A3500, Promega). 10 ng of cDNA, 5uL 2x SensiMix SYBR Lo-ROX
and 0.4 mL primers were applied for each RT-qPCR, which was
performed on a QuantStudio™ 7 Flex System. For each sample, the
real-time PCR was performed in duplicate. Data analysis was per-
formed with QuantStudio™ Real-Time PCR Software. Gene
expression levels were normalized to the expression of the refer-
ence gene glyceralde-3-phosphate dehydrogenase (GAPDH), which
was not influenced by the experimental conditions resulting in the
DCt value. Gene expression levels were calculated by the compar-
ative Ct method (2-DDCt) [38].
Primers for qRT-PCR were as follows:
GAPDH forward, 50- ACAGTCCATGCCATCACTGC-3’;
GAPDH reverse, 50- GATCCACGACGGACACATTG-3’;
IL-10 forward, 50- ATAACTGCACCCACTTCCCAGTC-3’;
IL-10 reverse, 50- CCCAAGTAACCCTTAAAGTCCTGC-3’;
IL-6 forward, 50- TGATGCTGGTGACAACCACGGC-3’;
F. Cao, S. de Weerd and D. Chen et al. European Journal of Medicinal Chemistry 208 (2020) 112800IL-6 reverse, 50- TAAGCCTCCGACTTGTGAAGTGGTA-3’;
TNFa forward, 50- CATCTTCTCAAAATTCGAGTGACAA-3’;
TNFa reverse, 50- GAGTAGACAAGGTACAACCC-3’;
miNOS forward, 50- CTATCAGGAAGAAATGCAGGAGAT-3’;
miNOS reverse, 50- GAGCACGCTGAGTACCTCATT-3’;
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